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correlated. Eighteen animals have been studied have been studies to assess the rate of
depreciation of the drugs over 6 months’ duration.
Results: Whereas specimens of the 2 S. aureus-treated unbonded grafts had high bacterial
counts (6.25106 and 1.38107 CFU/graft), specimens of the 2 S. aureus-treated bonded
grafts showed no bacterial growth. Bacterial growth in the 2 control pigs’ grafts (1.8103
and 7.27103 CFU/graft) reflected direct accidental perioperative bacterial contamina-
tion; the organisms isolated were not S. aureus (S. cohnii spp urealyticus and S.
chromogenes). The histopathologic and clinical data confirmed the microbiological
findings. Only pigs that received unbonded grafts showed histopathologic evidence of
perigraft abscess.
Conclusions: The quantitative results of our studies showed that bonding 3 antimicrobial
agents to aortic grafts prevented aortic graft infection by synergistically prolonging
antistaphylococcal activity. After the safety and preventive effect of this graft have been
further assessed, its use may be recommended for the in situ replacement of infected grafts
and possibly for routine primary cases, especially in immunocompromised patients,
patients with a hostile abdomen, and patients undergoing redo procedures.
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Background: This study reports the 2-year outcomes of the United States (US)
regulatory trial of the Endurant Stent Graft System (Medtronic Vascular, Santa Rosa, CA)
for the treatment of abdominal aortic aneurysms (AAA).
Methods: This was a prospective, single arm, multicenter trial conducted at 26 sites in the
US. From April 2008 to May 2009, 150 patients with AAA were treated with the
Endurant bifurcated stent graft. The main inclusion criteria were an AAA diameter 5
cm, proximal neck length 10 mm, bilateral iliac fixation length 15 mm, and a neck
angulation of60 degrees. The primary safety endpoint was freedom from major adverse
events at 30 days. The primary effectiveness endpoint was successful aneurysm treatment
at 12 months. Two years results are site reported.
Results: One hundred forty-nine patients (99.3%) had a successful implantation of the
Endurant stent graft. The one failure was due to the inability to cannulate the contralateral
gate. Patients within this trial were mostly male (91.3%), with a mean age of 73.1 and who
had significant comorbidities. Mean estimated blood loss was 185 mL (range, 0-1450 ml),
with one patient requiring a blood transfusion. The average hospital stay was 2.1 days.
Through the 24 month follow up, there were no ruptures, migrations or conversions to
open repair. The technical observations found no graft kinking or twisting, and no
fractures. A total of two (1.5%) stent graft occlusions were observed at the 2 year
follow-up. There were no type I or type III endoleaks observed at 24 months. Aneurysm
sac diameter decreased greater than 5mm occurred in 60.8% of patients and remained
stable in 36.9% of patients. There were only three patients (2.3%) that had an increase sac
of more than 5mm. There were no aneurysm related deaths (100% Freedom from ARM)
through two years.
Conclusions: The two year results of this pivotal trial continue to show that the Endurant
Stent Graft is a safe, durable, and effective device for the treatment of abdominal aortic
aneurysms.
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Background: Improvements in technique and devices promise improved outcomes
following endovascular repair of aneurysms of the descending thoracic aortic. This
mid-term report provides an update to the VALOR II trial results.
Methods: VALOR II is a prospective, multicenter, observational study of endovascular
treatment with the Valiant thoracic stent graft (Medtronic Endovascular Therapies, Santa
Rosa, Calif) in patients with descending thoracic aortic aneurysms (TAA) of degenerative
etiology.
Results: VALOR II enrolled 160 patients between December 2006 to September 2009
and 1-year results have been previously reported. In this update, follow-up was available
on 72% of patients through 3 years. One additional aneurysm-related death occurred after
1 year. One conversion to surgery was performed at 3 years in a patient who had
continued aneurysm expansion in the absence of any observable endoleak. Seven
secondary stent graft procedures were performed in 6 patients; 1 in the first 30 days, 3 after
1 year and 3 after 2 years. Freedom from secondary stent graft procedures was 94.9% at
3 years (95% CI: 88.8%-97.7%), which compared favorably with the earlier VALOR trial
(85.1% at 3 years; 95% CI: 78.5%-89.8%), a study of the Talent thoracic stent graft with
similar objectives and inclusion criteria. There was no type I or III endoleak reported at
2 or 3 years.
Conclusions: Mid-term results with the Valiant thoracic stent graft are acceptable and
compare favorably to an older generation device implanted in an earlier series of similar
patients. Long term results are needed to confirm this positive trend.
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Background: Out of 172 cases implanted worldwide we present the first 26 cases that
were scrutinized. All were Crawford thoraco-abdomial AAA. 75% were male with
median age of 73. Mean aneurysm diameter was 67mm with mean length of 167mm.
79.7% were ASA IV E. 62 % were redo after previous TEVAR.
Methods: Primary Endpoints are Freedom from Rupture and Aneurysm-related Death,
Aneurysm Sac and Lumen Volume Modulation, Patency of Visceral Branches, and
Freedom from Stroke and Paraplegia. Secondary Endpoints were technical success and
all-cause mortality. Finite Element Analyses was achieved on aortic sac pressure, shear
stress, wall displacement and blood flow velocities. All stents were deployed to their
intended target. No Aneurysm-related death occurred within 18 Months. No peri-
operative Visceral or Renal insult occurred. There were no Cerebro-vascular accidents,
paraplegia or loss of visceral branches patency. Two patients required reintervention
because of device foreshortening.
Results: At 6 months there was decline in average total sac volume, thrombus volume
and average diameter. Mean sac volume shrunk by 8% with lumen volume reduction of
14%. Average thrombus volume increased but thrombus to lumen ratio decreased by
23%. Finite Element Analysis post MFM documented dampening of wall displacement
by 80% with immediate depressurization of the aortic sac and dissipation of the maximum
pressure zone. There was 55% immediate reduction in Wall Stress.
Conclusions: MFM carries no risk of critical shuttering or loss of native side branches.
MFM offers immense promise for resolution of complex thoraco-abdominal aneurysms.
A Global MFM Registry is required and long-term follow-up is mandatory.
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Background: Out of 683 AAA operated upon, 120 patients presented with RAAA over
12 years, 42 had REVAR and 78 had OR.
Methods: Parallel Group comparison.
Results: Mean length of ICU was halved with REVAR VS OR (P0.008). Blood
product requirements were 60% less in REVAR (P0.0001). The Risk of ARDS and
cardiac events were doubled if OR were performed .However there were no statistical
significance in acute renal injury. Mean length of hospital stay was 7	/3 days for
REVAR , and 12	/6 for OR (P0.042).Thirty day mortality was 16% for REVAR vs
32% for OR ( P0.001). Total Emergency mortality rate decreased from 64% to 28.2%.
we attributed the Low Mortality Rate of 16%for REVAR Vs 32%in OR was due to
introduction of an REVAR Programme which constitutes screening for prevention with
early intervention and REVAR for rupture which has an absolute perioperative mortality
reduction of 49% over OR. 5 years Survival of Patients with RAAA were 75% REVAR
vs. 60% OR (p0.0205). During 20th century 95% of all AAA were done surgically.
However during 21st century 80% of AAA is done endovascularly. Mean Annual number
of OR dropped (P0.845) however Mean Annual number of EVARs had rocketed
(P0.006) . Overall number of AAA repairs has increased by 65% over twelve year’s
period but the absolute number of RAAA had declined by 24%.
Conclusions: Para-Millennium and Contemporary Trends in AAA Management had
shown Increased in Elective EVAR which increased the mortality advantage in favour of
REVAR and it should be the Gold standard for RAAA.
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Background: EVAR affords more propitious peri-operative and long-term survival than
Open Surgical Repair (OSR). However, up to 70% of AAAs are anatomically incompat-
ible with EVAR.
Methods: We aim to gauge the feasibility of applying commercially-available endografts
to pararenal aneurysms compared with OSR. Primary endpoints were aneurysm-related
survival and cost per Quality-Adjusted–Life-Years (QALY). From 2002-2009, 1868
patients with pararenal AAA were investigated. 118 had intervention and were described
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